Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label Trial of Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

NCT04910347 is registered in ClinicalTrials.gov with Yonsei University as lead sponsor.

NCT NCT04910347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04910347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label Trial of Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma
Lead sponsor
Yonsei University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 7, 2022
Completion date
May 31, 2031
Enrollment
57 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced nasopharyngeal carcinoma